Since the 1960s, the pace of innovation in haemophilia treatment has been fast and furious and occasionally with unintended consequences. As newer technologies are 
| INTRODUC TI ON
This is an unprecedented time for technological innovation in haemophilia treatment modalities, and in particular, for gene therapy. 1 For healthcare providers striving to prevent the damaging effects of poorly controlled bleeding, and the patients who have to cope with the risk and burden of haemophilia day in and day out, a path towards a cure is being established. For more than 30 years, since the clotting factor genes were cloned, [2] [3] [4] [5] [6] [7] "curing" haemophilia through gene transfer of factor VIII and factor IX genes has been anticipated.
Following initial failures in the 1990s, the community has speculated on whether 5% or 10% clotting factor activity was necessary to achieve in order to declare victory. No matter that 5%-10% activity will still require occasional use of protein clotting factor replacement therapy, ie, for severe trauma, target joints and surgery. These levels would turn individuals with severe haemophilia into moderate (1%-5%) or mild (>5%) phenotypes, 8 eliminating most of the burden and cost of frequent clotting factor replacement therapy. These 5%-10% levels, if stable, would also eliminate troughs intrinsic to intermittent replacement therapy, resulting in a substantial decrease in breakthrough bleeding episodes in most patients. 9 Importantly, 1%-2% trough levels are often insufficient in patients with severe haemophilic arthropathy and active synovitis; thus, prophylactic therapy has required an individualized and burdensome approach, sometimes necessitating higher trough levels to prevent breakthrough bleeding. 10, 11 In the late 1990s, 3 haemophilia A and 2 haemophilia B trials entered phase 1/2 studies (reviewed in 12, 13 ). The FVIII gene was delivered by ex vivo fibroblasts, a murine retrovirus and an adenovirus. The first haemophilia gene therapy trial, from Transkaryotic Therapies in 1998, transfected the FVIII gene as a plasmid into autologous skin fibroblasts, cultured them in vitro and implanted 100-400 million cells into the peritoneal cavity. 14 While some transient small increases in FVIII were seen in 4 of 6 subjects, the effect was not sustained, and the programme was discontinued. In hindsight, greater numbers of cells were likely required, 
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potentially with more enhanced implantation to assure access to a vascular and nutrient supply. Subsequently, a Moloney murine leukaemia virus (MoMLV) was utilized to deliver increasing doses of the BDD-FVIII gene intravenously. 15 
| CLOT TING FAC TOR E XPRE SS I ON IN PER SONS WITH HAEMOPHILIA
Scientific breakthroughs in 2015 suggest these previous results, remarkable in their own right, are not sufficient. Two groups, 1 pursuing factor IX gene therapy, and the other pursuing factor VIII, achieved higher expression levels in haemophilia gene therapy phase 1/2 clinical trials. The first, from Spark Therapeutics, 21 utilized a ~6-fold higher specific activity factor IX gene, the Padua mutation, in which a single R338L change was shown to lead to increased risk of thrombosis in 2 brothers in Italy. [22] [23] This mutation, coupled with gene and promoter optimization, packaged in a modified AAV8 vector, has enabled robust factor IX gene therapy, and Spark has achieved levels of 16%-81% in 10 patients sustained for a year and counting. 21 Average levels of circulating FIX were reported to be ~30%. There is an important precedent for curing haemophilia. Normal levels of FVIII and FIX are achievable upon liver transplantation, usually done in persons with haemophilia due to hepatitis C virusinduced cirrhosis. 26 Lessons learned from liver transplants include the fact that joint arthropathy from repeated bleeding remains and progresses, but acute bleeding generally stops and patients have complete freedom from the burden of clotting factor infusions. 27 In rare cases, a target joint persisting after liver transplant in an acute, inflamed state may bleed despite normal factor levels and may require an intervention such as synovectomy or embolization. 28 Thus, proof of principle that gene therapy of persons with haemophilia A or B produces a therapeutic result has been established.
How can this be translated into an established therapeutic modality?
| THE KNOWN S AND UNK NOWN S OF A AV-MED IATED G ENE TR AN S FER
The work to bring these pioneering therapies to patients is just starting, and many unknowns utilizing AAV-mediated gene transfer re- we know. We also know there are known unknowns; that is to say we know there are some things we do not know. But there are also unknown unknowns-the ones we don't know we don't know…."
Rumsfeld did not address a fourth category, the unknown known.
In this case, the person intentionally refuses to acknowledge known facts. 30 These distinct categories are a very useful lens with which to view human gene therapy, as stakeholders assess the benefit/risk ratio of an immature therapeutic modality. (Figure 1 )
What are the known knowns (Table 1) 
18,31
Interestingly, no evidence of a cytotoxic T-cell response was found to account for the transaminase increases in the BioMarin AAV5-FVIII trial, and an endoplasmic reticulum stress response appears unlikely, leaving the cause(s) of the self-limited transaminitis unresolved. 25 In another AAV5 trial, delivering the FIX gene, no evidence of a cytotoxic immune response was detected in subjects who had mildly elevated transaminases. 32 More recently, a variant of AAV9 delivering the SMN gene in nonhuman primates was found to induce an acute inflammatory response, similar to the innate immunity one might see in a viral infection that stimulates our more primitive immune systems. 33, 34 It will be important to sort out if this innate response is intrinsically tied to the AAV vector or to an undetected contaminant in the preparation. 45 The second cohort, at 5E12 vector copies/kg, achieved 5%-8%
FIX levels by 7-12 weeks, but also saw elevated transaminases in most patients, with an alanine aminotransferase (ALT) peaking at 914 IU/ dL in 1 patient. It should be pointed out that both the Baxter and Dimension studies used corticosteroids in 2 of 7 and 5 of 6, respectively, to attempt to rescue FIX, following Nathwani's protocol, 19, 20 without success. Thus, 2 independent clinical outcomes resulting in failed trials were unanticipated and are still not fully understood with respect to loss of efficacy and the liver safety signals.
Manufacturing of the drug is an important consideration.
Present scale, while sufficient for clinical trials, requires considerably more effort to achieve commercial scale. The ability to accurately assay the quality and quantity of the vector is not close to standardized, which makes comparisons between trials even using the same transgene problematic. For instance, whether a preparation is assayed for vector genomes or vector particles, how full, Despite these formidable challenges, gene therapy to cure haemophilia is on the horizon. For the 30% of the world which has access to standard of care therapy, the results are encouraging. However, for 70% of the world, the average lifespan is 10 years, 49 and haemophilia is very much a lethal disease. 49 Identifying solutions to offer gene therapy to individuals who have little hope of protein-based prophylactic clotting factor replacement therapy in the foreseeable future should be a priority as well.
| THE FUTURE
The future for gene medicines is encouraging, and haemophilia is leading the way. Current gene addition clinical trials utilizing AAV vectors could be considered first generation. They are able to produce therapeutic levels of FVIII or FIX through at least 1 year, but the therapy could be improved in a number of ways: improved AAV capsids that both decrease recognition from pre-existing antibodies and increase selective targeting to the tissue of interest in order to decrease doses required; gene editing to achieve chromosomal integration for lifelong gene expression, starting in infants; non-AAV vector delivery of the transgene.
The search for new AAVs is ongoing, and many new serotypes have been discovered. 50 Present mammalian AAV species originated in marsupials, AAV-EVE 45-27 million years ago. Based upon sequence analysis, 2 groups, primate and nonprimate mammals, have arisen. The primate group has been most studied and includes AAVs 1-4 and 6-13. AAV5 is the most studied nonprimate AAV and is closely related to AAV-Go.1, a serotype discovered in goats. 51 The close amino acid homology (94%) implies AAV5 originated in goat and was transmitted across species. These findings have implications for clinical utility, since the primate AAVs, all having >80% homology in their capsid proteins, have significant cross-reactivity with one another when pre-existing immunity is assessed. 41 Directed evolution and capsid shuffling are methods to develop novel capsids with predefined characteristics. The goals are twofold: to decrease recognition by pre-existing antibodies and to increase specific tissue targeting in an effort to decrease dose and/or increase efficacy. 52, 53 AAV is not thought to enable gene therapy of infants and children in whom livers are growing rapidly. Since it is a predominately nonintegrating vector, it is thought and has been shown in neonatal mice that the nuclear episomes in which the transgene resides are lost with progressive rounds of proliferation. One approach under nonclinical investigation is use of a non-cross-reactive serotype in a second injection. 54 Others have developed an integration strategy utilizing gene editing. In 1 permutation, the FIX gene utilizing a liverspecific promoter has been targeted to the albumin locus, 55 while
Barzel et al 56 have targeted a promoterless FIX to the albumin gene in order to utilize the albumin promoter in nonclinical experiments.
Both offer chromosomal integration, and presumably lifelong expression, and could offer neonates and small children with rapidly dividing hepatocytes the opportunity for gene therapy.
Finally, alternative vector systems are under investigation. The most promising utilizes lentivirus delivering the FIX gene intravenously to the liver. FIX activity up to 300% of normal was achieved in nonhuman primates. 57, 58 This group also used a modified FVIII delivered by lentiviral vectors to dogs and demonstrated FVIII activity 30%-100%. 59 Lentivirus offers integration, opening the possibility of treating young children if nonclinical safety studies warrant.
| NEED FOR NE W OUTCOME ME A SURE S TO A SS E SS CUR ATIVE THER APY
As much as gene therapy is innovative, it will require innovative approaches to assess its efficacy, safety and value as treatment for haemophilia. The disruptive impact of innovation is anticipated to impact the perceived value of, and maybe the willingness to use, treatment modalities currently considered standard of care.
| Efficacy outcomes
For assessment of efficacy, no new outcomes will be required, and, if anything, we will observe a return to the past. to support claims of improved efficacy of new treatment. [60] [61] [62] [63] [64] [65] The disruptive effect on gene therapy lies in that reaching near-normal or normal factor activity levels 21, 25 brings back the old concept of "proof of equivalence" required when replacement therapy was first introduced.
Consistently and stably restoring the lacking protein, and stopping bleeding, is all what FDA and other regulators should be looking at for efficacy, without need of comparative studies. 
| Safety outcomes
On the safety level, the innovative mechanisms of delivering gene therapy call for new specific outcomes. For example, one needs to know whether the manipulation of human genes and cells will induce other diseases, in particular cancer; if the genetic material transfected will be passed on to descendants or be eliminated in bodily fluids, 17, 25 and additional safety outcomes as listed in the 
| COS T-EFFEC TIVENE SS AND HE ALTH TECHNOLOGY A SS E SS MENT
After proving efficacious and safe, a treatment needs to prove it is worth its cost. Deciding on the cost for a treatment is a complex process. 70 On the manufacturer side, development and production costs have to be amortized over a period of time, dependent on forecast of uptake and lifespan for the treatment. Further, the business has to be profitable, which usually means, even in an "ethical sector" as health care, maximizing profit by setting the price closest to the highest acceptable point. On the payer side, the dynamic is opposite, ie, aiming for the lowest "fair" price, which payers, particularly in the framework of universal care provision, are seeking not because they are willing to compromise on patients' health, but because of the higher goal of spending the available funds where the return is highest. 71, 72 Due to the very peculiar characteristics of the Health Care market, the way the appropriateness of the price of drugs to society is assessed is health technology assessment (HTA). Based on HTA recommendations, health policymakers will make decisions about accessibility and pricing of new treatments. [73] [74] [75] Many economic analyses can be performed, from budget analysis to comparative effectiveness analysis. Specific outcomes used in economic analysis are direct and sometimes indirect health care expenditures, and measures of quality of life, usually transformed into utility measures, like the quality-adjusted life year (QALY). 76 Since the scope for HTA and coverage decision is ultimately comparing the return for investment among different treatments and choosing those treatments with the highest return (opportunity cost), 72 standardized generic measures (eg, SF-36, EQ-5D) have to be collected. 77, 78 Gene therapy will be no exception, and properly measuring QoL is key to success.
| VALUE PROP OS ITI ON S
Should the innovative treatment be better, and cheaper, HTA would identify it as a "dominant" treatment, and coverage and reimbursement decisions would be straightforward. In the more common situation of innovation coming at an incremental cost, a final layer of assessment is needed. Whereas the approach is still comparative, and outcome measures can still be QALY, the focus shifts on assessing the value of a treatment for a specific patient population. Measuring the value of an innovative treatment like gene therapy requires capturing the transformational impact of innovation on patient lives. 75, 76, [79] [80] [81] The impact of being cured from a congenital disease, experiencing the full suite of opportunities of a normal individual, is anticipated to have huge impact on the life experience of patients. There are not validated outcomes to measure this impact, the closest being measures of satisfaction, perception of a healthy body and psychological condition, chronic pain and its interference with daily life. 82 There is urgent need for identifying and adopting outcome measures appropriate to assess gene therapy in terms of value propositions. 83 CoreHEM, a project involving all relevant stakeholders (patients, researchers, clinicians, regulators, health technology assessors, payers and drug manufacturer) has identified, using a rigorous established methodology, a core set of outcomes covering the basic need of all the steps indicated above. 84 Its adoption in the upcoming phase III clinical trials in haemophilia will facilitate appropriate appraisal of gene therapy at all required levels.
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| ME A SURING OUTCOME S IN HAEMOPHILIA
Two final considerations are peculiar to the assessment of value for gene therapy in haemophilia. Gene therapy for haemophilia will compete, for its capacity to generate value, with gene therapy and innovative treatments for other diseases where there is no cure. Society may perceive the value is higher where there is no alternative. 70, 73, 74 For haemophilia, there are established and effective treatments. 85 There are also emerging ones, such as mimetics, recently shown at HTA assessment to be effective, safe and cost-effective, ie, able to reduce societal cost. 86, 87 In assessing value, gene therapy will be compared with them. Providing appropriate outcomes for the comparison has to be a community effort.
Even with the availability of a concerted core set of outcomes, measuring outcomes is a lengthy and demanding activity, needed both for patients receiving the new treatment and for some receiving the comparator in the real world. 85 There is no escape from providing comparative, convincing, robust evidence that the effects of gene therapy are worth its cost. Patients and their organizations in the community will need to work hard to collect comparative data, and prove to society that the benefits from gene therapy are valuable. Society can decide to pay the cost for the treatment, but the burden of proving its value will stay with the recipients. The new level of advocacy for treatment is evidence driven; many patient organizations, in this and other disease areas, have actively organized themselves to collaborate with regulators, payers and health technology assessor, have learned their language, produced the evidence they need to approve and provide the treatment they need.
The haemophilia community is continuing to move in this direction, and initiatives like coreHEM are showing this is an open opportunity.
| CON CLUS IONS
A new treatment modality is joining small molecules, peptides, recombinant proteins and other entities in the medical armamentarium. Unlike most other modalities, gene therapy is capable of curing, not simply treating, individuals with monogenic diseases.
As the field evolves, outcome measures that can capture the medical and psychosocial differences between treatment and a cure will be important to establish for pharmacoeconomic assessment of curative technologies. As important, elucidating the safety implications of known unknowns and unknown unknowns also will be critical for gene therapy to fulfill it's long anticipated promise.
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